Gender Differences in Efficacy and Tolerability of Opicapone in Add on of Levodopa. A Single-Center Retrospective Cohort Study - PubMed

4 hours ago

Opicapone is a COMT inhibitor used as an add-on to levodopa for Parkinson's disease (PD) patients with motor fluctuations.
A retrospective cohort study evaluated gender differences in efficacy and tolerability of opicapone.
Men with PD showed a significant reduction in total daily OFF time after opicapone treatment.
Adverse events (AEs) were reported by 41.6% of patients, with dyskinesia being the most common.
Women had a significantly higher incidence of AEs (65.4%) compared to men (29.4%).
Female sex was significantly associated with the presence of AEs (OR 4.08).
Women also had higher odds of discontinuing opicapone (OR 3.00).
The study suggests reducing levodopa dosage in women before introducing opicapone to avoid early discontinuation due to AEs.
The study provides new insights into gender differences in PD treatment.

Hasty Briefsbeta